<DOC>
	<DOCNO>NCT00145639</DOCNO>
	<brief_summary>This trial ( OS99 ) evaluate use ifosfamide , carboplatin , doxorubicin up-front window surgery localize resectable osteosarcoma . High-dose methotrexate , may interfere dose-intensive delivery agent , eliminate treatment localized disease . The primary objective compare response rate pre-surgical chemotherapy comprise ifosfamide , doxorubicin , carboplatin obtain ifosfamide carboplatin St. Jude OS-91 trial patient non-metastatic resectable osteosarcoma . We hypothesize histologic response rate improve addition one course pre-operative chemotherapy trial compare previous OS-91 trial .</brief_summary>
	<brief_title>Osteosarcoma1999-A Study Of Intensive Chemotherapy Osteosarcoma</brief_title>
	<detailed_description>This study multiple research objective : - To compare response rate pre-surgical chemotherapy comprise ifosfamide , doxorubicin , carboplatin obtain ifosfamide carboplatin St. Jude OS-91 trial patient non-metastatic resectable osteosarcoma - To continue evaluation dynamic contrast-enhanced magnetic resonance imaging ( DEMRI ) predict tumor response accurately assess degree response ( continued OS-91 ) . - To determine feasibility deliver outpatient-based chemotherapy osteosarcoma use ifosfamide-doxorubicin-carboplatin . - To determine whether resection primary site may satisfactorily perform 3 cm margin normal bone ( rather 5 cm ) . - To study biologic biochemical characteristic tumor cell may prognostic significance - To study patient ' parent ' perspective patient ' quality life treatment . Description Treatment Plan : This study employ follow treatment strategy : neoadjuvant chemotherapy follow definitive surgery local control adjuvant chemotherapy tumor resection . Pre-operative chemotherapy phase ( week 0-12 ) : Three course ifosfamide/carboplatin give every 3 week follow one 3-week course doxorubicin.Disease evaluation perform 3 course 4 course chemotherapy . Weeks 0 , 3 , 6 - Ifosfamide-Carboplatin Ifosfamide : 2.65 gm/m2 IV daily 15-30 minute x 3 ( Days 1 , 2 , 3 ) MESNA . Carboplatin : dose base GFR target AUC 8 mg/mL/min , give IV 1 hour ( Day 1 ) Week 9- Evaluation , follow Doxorubicin Doxorubicin : 25 mg/m2 IV 1 hour , daily x 3 Week 12 Evaluation follow definitive Surgery Local control amputation limb-salvage procedure Post-operative chemotherapy ( Weeks 14-35 ) Ifosfamide , carboplatin , doxorubicin two-agent pair approximately 35 week . Week 14 - Ifosfamide-Doxorubicin Ifosfamide : 2.65 gm/m2 IV daily 15-30 minute x 3 ( Days 1 , 2 , 3 ) MESNA , Doxorubicin : 25 mg/m2 IV 1 hour , daily x 2 ( Days 1 2 ) Week 17 - Ifosfamide-Carboplatin Ifosfamide : 2.65 gm/m2 IV daily 15-30 minute x 3 ( Days 1 , 2 , 3 ) MESNA , Carboplatin : target AUC 8 mg/mL/min give IV 1 hour ( Day 1 ) Week 20 - Carboplatin-Doxorubicin Carboplatin : target AUC 8 mg/mL/min give IV 1 hour ( Day 1 ) , Doxorubicin : 25 mg/m2 IV 1 hour , daily x 2 ( Days 1 2 ) Week 23 - Evaluation , follow Ifosfamide : Doxorubicin . Ifosfamide : 2.65 gm/m2 IV daily 15-30 minute x 3 ( Days 1 , 2 , 3 ) MESNA , Doxorubicin : 25 mg/m2 IV 1 hour , daily x 2 ( Days 1 2 ) Week 26 - Ifosfamide-Carboplatin Ifosfamide : 2.65 gm/m2 IV daily 15-30 minute x 3 ( Days 1 , 2 , 3 ) MESNA , Carboplatin : target AUC 8 mg/mL/min give IV 1 hour ( Day 1 ) Week 29 - Carboplatin-Doxorubicin Carboplatin : target AUC 8 mg/mL/min give IV 1 hour ( Day 1 ) , Doxorubicin : 25 mg/m2 IV 1 hour , daily x 2 ( Days 1 2 ) Week 32 - Evaluation , follow Ifosfamide-Doxorubicin . Ifosfamide : 2.65 gm/m2 IV daily 15-30 minute x 3 ( Days 1 , 2 , 3 ) MESNA , Doxorubicin : 25 mg/m2 IV 1 hour , daily x 2 ( Days 1 2 ) Week 35 - Carboplatin-Doxorubicin Carboplatin : target AUC 8 mg/mL/min give IV 1 hour ( Day 1 ) , Doxorubicin : 25 mg/m2 IV 1 hour , daily x 2 ( Days 1 2 )</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>All subject histologically proven highgrade osteosarcoma , chondrosarcoma , MFH , fibrosarcoma chondrosarcoma bone , whose tumor potentially resectable ( either limb sparing , en bloc resection , amputation ) evidence metastasis . Adequate liver , renal cardiac function . Age : Younger 25 year old Prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Osteosarcoma</keyword>
	<keyword>Treatment , Carboplatin</keyword>
</DOC>